Andy

BETHESDA, Md. & WEST JEFFERSON, Ohio–(BUSINESS WIRE)–Vitrian, the leading end-to-end provider of investment capital and capacity building services for biomanufacturing, announced today that it closed a $50 million investment, with ability to scale to $65 million, into AmplifyBio’s Manufacturing Enablement Center (AMEC) in New Albany, Ohio as a first step of a larger commitment to support biomanufacturing in Central Ohio. AmplifyBio is a leading advanced therapy CRO and CDMO offering a full range of drug development and manufacturing services.

10 groundbreaking startups to pitch at Richmond’s Main Street Station on November 20, 2024

RICHMOND, Va., Nov. 4, 2024 /PRNewswire/ — Activation Capital, an innovation ecosystem development organization, is thrilled to announce the Frontier BioHealth Showcase, an event highlighting the achievements of 10 fast-growing life science startups that have completed the inaugural Frontier BioHealth program. Taking place on November 20 at Main Street Station in downtown Richmond, VA, the event kicks off with networking and beverages in the Head House at 4 pm, followed by the Showcase in the Concourse Room at 5 pm, where each startup will deliver a five-minute pitch to an audience of mentors, investors, and community leaders.

Germantown, Maryland, and Venlo, the Netherlands, Nov. 04, 2024 (GLOBE NEWSWIRE) — QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx Meningitis/Encephalitis Panel for clinical use.

This marks the fourth QIAstat-Dx syndromic test to receive U.S. regulatory clearance in 2024.

Meningitis (inflammation of the membrane surrounding the brain and spinal cord) and encephalitis (inflammation within the brain) are medical emergencies that require immediate treatment. One in five cases of bacterial meningitis results in permanent complications, such as hearing loss, brain damage and seizures and without prompt treatment, about half of patients will die.[1]

Nov 3, 2024 LaunchPort is pleased to announce that Nanochon (https://www.nanochon.com/) has joined their City Garage/Baltimore Peninsula location as a LaunchPort Resident.

Nanochon’s mission is to develop a new approach to treat cartilage replacement and repair so that the hundreds of thousands of young, active patients with knee damage can return to their lifestyles without having to undergo costly and invasive short-term fixes. Founded in 2016, their technology is a minimally-invasive early intervention that could help avert the need for total knee replacement. Nanochon’s Chondrograft device is a sturdy medical advancement that is one part orthopedic load-bearing implant, one part tissue growth scaffold, and completely revolutionary. Their implant replaces lost or damaged cartilage and encourages new growth using innovative nanomaterial and 3-D printed designs. This technology has the potential to provide a more successful, faster, longer-lasting, and more affordable solution to joint disease and injury.

In this episode of BioTalk, Rich Bendis sits down with Rachel Rath, the Head of JLABS @ Washington, DC, to discuss her journey and insights on building a thriving ecosystem for life sciences innovation. Rachel shares her academic and professional background, from roles at PCORI and BARDA Blue Knight to leading JLABS @ Washington, DC. She offers an in-depth look at JLABS’ national and international footprint, and the significant partnerships with organizations like Children’s National, Virginia Tech, and BARDA that strengthen the innovation landscape across the mid-Atlantic.

Tune in as Rachel shares the current priorities at JLABS, highlighting the diversity of its tenant portfolio, which spans MedTech, Pharma, and Integrated Healthcare Solutions. She also discusses how JLABS companies benefit from the support and resources available through Johnson & Johnson, including access to valuable connections, mentorship, and funding opportunities via JJDC.

Listen now via your favorite podcasting platform:

Apple: https://apple.co/4fybjcO
Spotify: https://spoti.fi/4eenlXO
Amazin Music: https://amzn.to/3NRxK0P
TuneIn: https://bit.ly/4ecryv7

The Indo US Bridging RARE Summit 2024 is set to be an unmissable event for those dedicated to advancing rare disease research and fostering global collaborations. Taking place from November 16-18, 2024, this second annual summit is hosted by the Indo US Organization for Rare Diseases (IndoUSrare) in partnership with AIIMS (All India Institute of Medical Sciences, New Delhi) and other key partners. The main venue is the Indian National Science Academy (INSA) Campus, New Delhi, with an opening gala at the outdoor AIIMS Swimming Pool Venue on the evening of November 16th. Virtual participation will be available, offering opportunities for online networking, exhibits, and posters.

FREDERICK, MARYLAND, November 4, 2024: BioFactura, Inc. recently announced contract option activations totaling $7.8 million by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services, as part of BioFactura’s prime contract valued at up to $78 million for the advanced development of a Smallpox Biodefense Therapeutic. This monoclonal antibody cocktail therapeutic has the potential to augment current medical countermeasures, guard against potential resistance of the Smallpox virus, and fulfill an unmet need in our nation’s biothreat preparedness.

COLUMBIA, Md., (October 31, 2024) — TEDCO, Maryland’s economic engine for technology companies, announced a recent $250,000 Seed Funds investment in NeuroIntact. TEDCO’s Seed Funds aim to reach prospective businesses showing potential of being venture fundable or other forms of corporate venture, such as follow-on funding.

“Elevated pressure in the brain as a result of a cerebral edema can be not only damaging, but also life-threatening without proper treatment,” said Bryan Nicholson, president of NeuroIntact. “That’s why we’re working on creating a solution and thanks to this recent investment from TEDCO, we can continue progressing in our research and development efforts.”